Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
Primary Purpose
Stress Urinary Incontinence
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Non-ablative thermal-only Er:YAG laser therapy
Sponsored by
About this trial
This is an interventional treatment trial for Stress Urinary Incontinence focused on measuring stress urinary incontinence, non-ablative Er:YAG laser
Eligibility Criteria
Inclusion Criteria:
- Adult Female, 18 years of age or older
- Clinical and urodynamic study (UDS) diagnosis of Stress Urinary Incontinence
- No significant improvement in urinary incontinence from at least one previous conservative treatment, such as pelvic floor muscle training
Exclusion Criteria:
- Pre-existing bladder pathology including prior radiation treatment
- Pregnancy
- BMI>35
- Radical pelvic surgery or previous incontinence surgery
- Urinary tract infection or other active infections of urinary tract or bladder
- SUI III (VLPP > 60 cm H2O)
- Any form of pelvic organ prolapse (POP) stage 2 or greater, according to POP-Q
- Diagnosis of urge incontinence
- Diagnosis of collagen disorders eg.benign joint hypermobility / Elhers-Danlos / Marfans etc.
- Incomplete bladder emptying
- Vesicovaginal fistula
- Faecal incontinence
- Unwillingness or inability to complete follow-up schedule
- Unwillingness or inability to give Informed Consent
- Failure to comply with diary requirements during extended baseline period
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Laser therapy
Arm Description
Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
Outcomes
Primary Outcome Measures
Assessment of ICIQ-UI SF scores
Change in mean test scores range = 0 - 21; low score = mild symptoms, high score = significant impact on quality of life.
Assessment of 1 hour pad weight test
The change in standardised 1 hour pad weight test from baseline to 36 months following treatment schedule.
Secondary Outcome Measures
Change in 24 hour pad weight test
The change in standardised 24 hour pad weight test from baseline to 36 months following treatment schedule.
Change in leakage frequency as assessed by 3 day voiding diary
The change in leakage frequency from baseline to 36 months following treatment schedule.
Full Information
NCT ID
NCT04348994
First Posted
April 14, 2020
Last Updated
April 15, 2020
Sponsor
Adrian Gaspar
Collaborators
Fotona d.o.o.
1. Study Identification
Unique Protocol Identification Number
NCT04348994
Brief Title
Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
Official Title
3-year Follow up of Patients With Stress Urinary Incontinence Treated With Minimally Invasive Er: YAG Laser
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
March 1, 2015 (Actual)
Primary Completion Date
September 1, 2018 (Actual)
Study Completion Date
December 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Adrian Gaspar
Collaborators
Fotona d.o.o.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Study is designed to assess the long-term clinical effects and safety profile of non-ablative Er:YAG (IncontiLase®) laser treatment, the durability of the results and the optimal treatment regimen for mild-to-severe stages of genuine female stress urinary incontinence (SUI).
Detailed Description
All patients with urodynamically proven SUI, who have failed/declined conservative therapies will be informed about the study.
They will be invited to attend a screening/baseline visit. At this visit, they will be asked to perform a standardised 1 hour pad test. Their medical history will be checked and they will undergo a clinical and vaginal examination, pregnancy test and dip stick urinalysis. If their 1 hour pad weight is >2g and they meet all other inclusion / exclusion criteria, they will be eligible for inclusion. They will receive detailed instructions for performing a 24 hour pad test, and will be asked to keep a 3 day voiding diary. They will be given the International Consultation on Incontinence Questionnaire Short Form (ICIQ-UI SF).
Patients will then undergo 3 outpatient treatment visits. The timing of visits will be approximately 1 month apart. At each of their 3 outpatient appointments, they will be asked about any deleterious effects since their last appointment. Patients will receive 3 treatments in total.
Patients will be invited to attend a follow-up visits 3, 6, 12 and 18 months after the 3rd treatment and asked to complete the 1 hour pad test, 24 hour pad test, 3 day voiding diary and ICIQ-SF questionnaire.
At the 18-, 24- and 30-month follow up, they will be given an option to receive additional single session of non-ablative Er:YAG laser treatment. At each visit, and during additional visit after 36 months, they will be asked to complete all of the tests (1 hour pad test, 24 h hour pad test, 3 day voiding diary and ICIQ-UI SF).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence
Keywords
stress urinary incontinence, non-ablative Er:YAG laser
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Laser therapy
Arm Type
Experimental
Arm Description
Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
Intervention Type
Device
Intervention Name(s)
Non-ablative thermal-only Er:YAG laser therapy
Other Intervention Name(s)
IncontiLase®
Intervention Description
Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).
Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions.
Primary Outcome Measure Information:
Title
Assessment of ICIQ-UI SF scores
Description
Change in mean test scores range = 0 - 21; low score = mild symptoms, high score = significant impact on quality of life.
Time Frame
Baseline, 3, 6, 12, 18, 24, 30 and 36 months
Title
Assessment of 1 hour pad weight test
Description
The change in standardised 1 hour pad weight test from baseline to 36 months following treatment schedule.
Time Frame
Baseline, 3, 6, 12, 18, 24, 30 and 36 months
Secondary Outcome Measure Information:
Title
Change in 24 hour pad weight test
Description
The change in standardised 24 hour pad weight test from baseline to 36 months following treatment schedule.
Time Frame
Baseline, 3, 6, 12, 18, 24, 30 and 36 months
Title
Change in leakage frequency as assessed by 3 day voiding diary
Description
The change in leakage frequency from baseline to 36 months following treatment schedule.
Time Frame
Baseline, 3, 6, 12, 18, 24, 30 and 36 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult Female, 18 years of age or older
Clinical and urodynamic study (UDS) diagnosis of Stress Urinary Incontinence
No significant improvement in urinary incontinence from at least one previous conservative treatment, such as pelvic floor muscle training
Exclusion Criteria:
Pre-existing bladder pathology including prior radiation treatment
Pregnancy
BMI>35
Radical pelvic surgery or previous incontinence surgery
Urinary tract infection or other active infections of urinary tract or bladder
SUI III (VLPP > 60 cm H2O)
Any form of pelvic organ prolapse (POP) stage 2 or greater, according to POP-Q
Diagnosis of urge incontinence
Diagnosis of collagen disorders eg.benign joint hypermobility / Elhers-Danlos / Marfans etc.
Incomplete bladder emptying
Vesicovaginal fistula
Faecal incontinence
Unwillingness or inability to complete follow-up schedule
Unwillingness or inability to give Informed Consent
Failure to comply with diary requirements during extended baseline period
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35067817
Citation
Gaspar A, Koron N, Silva J, Brandi H. Vaginal erbium laser for treatment of stress urinary incontinence: optimization of treatment regimen for a sustained long-term effect. Lasers Med Sci. 2022 Jun;37(4):2157-2164. doi: 10.1007/s10103-021-03474-z. Epub 2022 Jan 24.
Results Reference
derived
Learn more about this trial
Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
We'll reach out to this number within 24 hrs